- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01405222
Cough Frequency in Chronic Obstructive Pulmonary Disease
Objective Measure of COPD Exacerbation Using the Hull Automated Cough Recorder. Verifying Use of Automated Recording Systems in Measuring Symptoms Associated With a COPD Exacerbation
Study Overview
Status
Conditions
Detailed Description
Acute exacerbations of COPD remain a common cause of morbidity and are associated with a sustained increase in the respiratory symptoms of dyspnoea, cough, sputum volume and sputum purulence. Cough is one of the most commonly reported and key symptoms in COPD patients. Cough can also be a useful factor in finding patients at risk of progressive airflow obstruction and cough along with the breathlessness is the major cause of distress in patients with chronic obstructive airways disease (COPD). There is limited literature looking into cough and COPD especially objective assessments.
in clinical practice and in most clinical trials scoring systems ie quality of life questionnaires or visual analogue scores, have been used to measure COPD exacerbation severity, although these may give an indication of the perceived severity of the symptom, they are inherently subjective and may be influenced by other factors. Shortfalls have prompted the development of cough recorders as an objective measure of this symptom. With this in mind we propose recruit 30 subjects with non-infective exacerbations of COPD and monitor their cough frequency as an inpatient in acute exacerbation and for 45 days post hospital discharge in order to elucidate the natural history of cough during and after an exacerbation.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
East Yorkshire
-
Cottingham, East Yorkshire, United Kingdom, HU16 5JQ
- Redspiratory medicine, Clinical trials Unit, Castle Hill hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male/females aged between 40-80 years.
- Previous diagnosis of COPD.
- Acute exacerbation of COPD requiring treatment with antibiotics and/or corticosteroids.
- Symptoms of increased breathlessness, cough, sputum volume or sputum purulence.
- Acute exacerbation of COPD hospitalised within 48 hrs of study participation.
- On a stable therapeutic regimen for COPD for 8 weeks prior to inclusion.
- Known history of cigarette smoking at least 10 pack yrs.
- Willing and able to comply with study procedures.
- Able to provide written informed consent to participate.
Exclusion Criteria:
- Acute exacerbation of COPD within 8 weeks prior to inclusion.
- Clinically significant or unstable concurrent disease e.g. left ventricular failure, diabetes mellitus.
- On long-term oxygen therapy.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Acute COPD exacerbation
Patients admitted in to hospital with an acute exacerbation of COPD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in recorded cough counts/hr
Time Frame: 5 days
|
The primary objective is to evaluate the effectiveness of Hull Automated Cough Counter in recording transition of an acute COPD exacerbation.
Change in no coughs/hr will be measured between start of exacerbation (day 0) to day 5 of exacerbation
|
5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
compare cough/hr measured via Hull automated cough counter with that of Phillips 45 day cough monitor
Time Frame: 45 days
|
The Key secondary endpoint will be to validate automated cough counts measured via the HACC with those measured via the Phillips 45CM at day 1, 5, 20 and 45.
Cough monitor results will be compared using a bland altman plot, to determine if the systems are comparative with on another
|
45 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Alyn H Morice, MD, MPhil, Hull University Teaching Hospitals NHS Trust
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 25042011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD Exacerbation
-
University Medical Center GroningenCompleted
-
Sociedad Española de Neumología y Cirugía TorácicaGlaxoSmithKlineNot yet recruitingCOPD Exacerbation
-
University of Tennessee Graduate School of MedicineMylan Pharmaceuticals IncRecruiting
-
Malcolm KohlerDeep Breath Intelligence (DBI)RecruitingCOPD ExacerbationSwitzerland
-
Universidad Autonoma de MadridCompleted
-
Guy's and St Thomas' NHS Foundation TrustCompleted
-
Hospital Universitario Marqués de ValdecillaGlaxoSmithKlineUnknown
-
Hospital Universitario Marqués de ValdecillaRecruiting
-
Ottawa Hospital Research InstituteCompleted
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI)CompletedCOPD ExacerbationUnited States